PROVIDER
REIMBURSEMENT
SUPPORT
This convenient program includes
insurance benefit investigation and
prior authorization support, and
timely status updates.
Available Monday-Friday, 9 AM to 8 PM ET
Fax: 1-877-447-9734
For patient insurance verification, register/login to: www.fidiacomplete.com
HYMOVIS® ONE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic
therapy or simple analgesics (e.g., acetaminophen).
HYMOVIS® ONE is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram-positive bacterial proteins. Do not administer
HYMOVIS® ONE to patients with infections or skin diseases in the area of the injection site or joint. The safety and effectiveness of HYMOVIS® ONE have not been established in
pregnant women, nursing mothers, or children, or for use in joints other than the knee, or for concomitant use with other intra-articular (IA) injections. The effectiveness of
repeat treatment cycles of HYMOVIS® ONE has not been established. No serious adverse events or pseudoseptic reactions were reported in the HYMOVIS® ONE clinical study.
The adverse events experienced and reported in the HYMOVIS® ONE clinical study were joint swelling, metatarsalgia, neck pain, and headache.
Rx Only. See package insert for full prescribing information, including indications, contraindications, adverse events, warnings, precautions, and side effects.
References:
2. HYMOVIS® ONE Package Insert. Fidia Farmaceutici S.p.A., Abano Terme, Italy; 2025.
4. HYMOVIS® ONE Summary of Safety and Effectiveness Data (SSED) P150010/S005.
